A capsaicin-based therapy developed by University of Wyoming scientists showed promise in mouse models of obesity.

Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.

Novartis will take MOR106 forward in atopic dermatitis and other indications, handing over up to €850 million in milestones as it goes.

The deal sees Kite take a stake in Gadeta and commit to milestones tied to the progress of oncology candidates.

IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.

The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.

Pfizer and Eli Lilly’s NGF inhibitor tanezumab is closer to becoming an alternative to opioid analgesics for pain after a positive phase 3 trial.

The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year.

The voted-for text tasks the government with seeking to secure the right for the U.K. to “fully participate” in the EMA after Brexit.

electroCore and UpScriptHealth will offer the former's gammaCore vagus nerve stimulation treatment through a telemedicine program.